In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice

Immunology

Volumn 87, Issue 4, 1996, Pages 633-641

  Bost, K L ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 13; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; LYMPH NODE; MOUSE; MUCOSA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SPLEEN CELL;

EID: 0029869729     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1996.502574.x     Document Type: Article

References (3)

1. BROWN K.D., ZURAWSKI S.W., MOSSMAN T.R. & ZURAWSKI G. (1989) A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 142, 679.
2. McKENZIE A.N.J., CULPEPPER J.A., DE WAAL MALEFYT R. et al. (1993) Interleukin-13, a novel T cell-derived cytokine that regulates monocyte and B cell function. Proc Natl Acad Sci USA 90, 3735.
3. MINTY A., CHALON P., DEROCQ J.-M. et al. (1993) Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature.362, 248.